Abcam Announces Markus Lusser As President To Spearhead Next Phase Of Innovation

In a significant move within the life sciences sector, Abcam has announced Markus Lusser as its new President. This appointment marks a crucial phase for Abcam as it becomes part of the Danaher Life Sciences portfolio. With a rich background in commercial and digital arenas across life sciences and medical device industries, Lusser is set to enhance Abcam's trajectory towards delivering innovative solutions that cater to customer needs and advance the industry.

Lusser's journey with Danaher began in 2011, culminating in his role as Vice President and Chief Customer Officer for the Life Sciences Innovations Group. In this capacity, he was instrumental in shaping and implementing Danaher's strategy across its operating companies (OpCo), driving growth and market share in the biologics segment. His tenure as President of Leica Microsystems (LMS) saw him spearheading innovation, commercial execution, and associate engagement, which resulted in accelerated growth, improved profitability, and cash flow. Notably, under his leadership, LMS launched ARveo, the pioneering Surgical Imaging Platform with Augmented Reality capabilities for brain surgery.

Before his tenure at Danaher, Lusser managed large global commercial organizations, including a 20-year stint at Siemens Healthineers. He holds an Engineering degree in Electronics from HTBLA in Innsbruck, Austria. Known for his people-centric leadership approach, Lusser is committed to nurturing cross-functional teams, fostering customer-centric cultures, and leveraging collective expertise to benefit customers and stakeholders alike.

Expressing his enthusiasm about his new role, Lusser stated, "I am excited to join Abcam and work alongside such talented and diverse teams to solve complex challenges and help our customers progress faster, together." He aims to cultivate a culture that prioritizes customer needs, ensuring quality products, close partner collaboration, and a focus on industry innovation.

Lusser steps into the shoes of Alan Hirzel, who has been at the helm of Abcam as CEO since 2014. Abcam, headquartered in Cambridge, UK since 1998, boasts a significant global presence with nine sites operating in over 130 countries. The company employs more than 1,750 associates and serves 750,000 researchers worldwide.

About Abcam: Founded with the mission to supply high-quality biological reagents to life scientists globally, Abcam now supports 750,000 researchers across 130 countries in achieving faster scientific breakthroughs. The company plays a pivotal role in fundamental research along with drug discovery, diagnostic, and therapeutic applications. For more information on how Abcam is innovating to assist scientists in propelling their research forward, visit www.abcam.com and www.corporate.abcam.com.